

ASX Announcement

Medibio Limited – 25 OCTOBER 2017



Receipt of \$3,266,997 R&D Tax Incentive Refund

Sydney, Australia and Minneapolis, MN – 25 October 2017: Medibio Limited (ASX: MEB)(OTCQB: MDBIF) is pleased to announce that it has received \$3,266,997 from the Australian Taxation Office under the Research and Development Tax Incentive Program. The cash refund is related to expenditure on eligible Australian and Overseas R&D activities conducted during the financial year ended June 30, 2017.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN and Palo Alto, CA. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market www.otcmarkets.com and www.asx.com.au.

Further Information: Website: www.medibio.com.au	
Medibio Shareholder Enquiries: Jack Cosentino CEO and Managing Director Medibio Limited jack.cosentino@medibio.com.au T: +1 (952) 465 4787	Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231